Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy with an unfavorable prognosis. It predominantly manifests with cutaneous lesions, which are frequently asymptomatic and can range from solitary to multiple, covering a wide area. These skin manifestations can vary from bruise-like discolorations to plaques or nodules. Additionally, patients may exhibit bone marrow involvement, infiltration of the central nervous system (CNS), lymph node enlargement, spleen enlargement, and various degrees of cytopenias. Within the dendritic cell and histiocytic neoplasms category, BPDCN is grouped alongside plasmacytoid dendritic cell proliferation associated with myeloid neoplasms. BPDCN primarily affects older men, with a male-to-female ratio ranging from 3:1 to 5:1, typically diagnosed between 60 and 70. The most common initial clinical presentation of BPDCN involves asymptomatic skin lesions, occurring in approximately 90% of patients at diagnosis. These skin lesions can manifest as areas resembling bruises, patches, plaques, or nodules. While some individuals may exhibit exclusively skin-related symptoms, most also demonstrate BPDCN involvement in the bone marrow, lymph nodes, and visceral organs. In rare instances, patients may present with a leukemic phase of the disease without any apparent skin lesions. CNS involvement is observed in around 30% of patients, and BPDCN can manifest in less common sites such as soft tissues, the breast, gallbladder, tongue, and lung. Some patients may also have concomitant myeloid neoplasms like CMML, MDS, and AML, referred to as prior or concurrent hematologic malignancy (PCHM). Although a small percentage of patients may have isolated skin involvement, most will also have BPDCN detected in the bone marrow, lymph nodes, or visceral organs. Unfortunately, the prognosis for most patients is grim, with a survival period of only 10 to 14 months post-diagnosis, despite receiving various chemotherapy treatments. Allogeneic stem cell transplantation (alloSCT) represents the sole potentially curative treatment option for BPDCN. However, due to the preponderance of this disease in older individuals, only a minority of BPDCN patients are suitable candidates for alloSCT. BPDCN predominantly affects males, with a male-to-female ratio of approximately 3.3:1, typically occurring in the seventh or eighth decade of life.

·       It has an estimated incidence rate of about 0.04 cases per 100,000 individuals, although it can manifest at any age, including childhood.

 

Thelansis’s “Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market outlook, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) competitive landscape, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypoglycemia and severe
Read more